![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer’s Bavencio Approved for Bladder Cancer
Pfizer’s Bavencio Approved for Bladder Cancer
July 2, 2020
The FDA has approved Pfizer’s Bavencio (avelumab) as a maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma that has not responded to first-line platinum-containing chemotherapy.
The approval is based on the results of a phase 3 trial, in which patients treated with Bavencio along with best supportive care demonstrated a median survival of 21.4 months compared to 14.3 months for those given best supportive care alone.
Bavencio received a Breakthrough Therapy designation and a streamlined review under the FDA’s Real-Time Oncology Review pilot program.
Upcoming Events
-
21Oct